Cloudbreak®
DFCs for Oncology

Cidara is developing a new generation of immunotherapeutic agents from its Cloudbreak platform that couple potent drugs to a human antibody fragment. These highly potent, long-acting drug-Fc conjugates (DFCs) are designed to inhibit specific disease targets while simultaneously engaging the immune system.

Overview

Influenza

HIV, RSV, SARS-CoV-2
And Other Viruses

Oncology

DFCs have the potential to become novel treatments for cancer. Discovery efforts are ongoing.

Subscribe here for updates.